Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation

Journal of Bone and Mineral Research

Volumn 29, Issue 7, 2014, Pages 1541-1553

  Kim, Ju Young ^a   Cheon, Yoon Hee ^a   Kwak, Sung Chul ^a   Baek, Jong Min ^a   Yoon, Kwon Ha ^a   Lee, Myeung Su ^a   Oh, Jaemin ^a  

^a Wonkwang University   (South Korea)

Author keywords

BONE REMODELING; EMODIN; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS

Indexed keywords

EMODIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; ALKALINE PHOSPHATASE; NFATC1 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE EROSION; BONE GROWTH; BONE MARROW; BONE MARROW CELL; BONE MINERALIZATION; BONE REMODELING; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; ADULT; ANIMAL; BONE DEVELOPMENT; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM;

ADULT; ALKALINE PHOSPHATASE; ANIMALS; CELL DIFFERENTIATION; EMODIN; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, INBRED ICR; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOBLASTS; OSTEOCALCIN; OSTEOCLASTS; OSTEOGENESIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND;

EID: 84903271032     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2183     Document Type: Article

References (54)

1. Grabowski P., Physiology of bone. Endocr Dev. 2009; 16: 32-48.
2. Kartsogiannis V, Ng KW., Cell lines and primary cell cultures in the study of bone cell biology. Mol Cell Endocrinol. 2004; 228 (1-2): 79-102.
3. Goltzman D., Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov. 2002; 1 (10): 784-96.
4. Sims NA, Walsh NC., Intercellular cross-talk among bone cells: new factors and pathways. Curr Osteoporos Rep. 2012; 10 (2): 109-17.
5. Matsuo K, Irie N., Osteoclast-osteoblast communication. Arch Biochem Biophys. 2012; 473 (2): 201-9.
6. Ducy P, Schinke T, Karsenty G., The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000; 289 (5484): 1501-4.
7. Blair HC, Zaidi M, Schlesinger PH., Mechanisms balancing skeletal matrix synthesis and degradation. Biochem J. 2002; 364 (Pt 2): 329-41.
8. Yang X, Karsenty G., Transcription factors in bone: developmental and pathological aspects. Trends Mol Med. 2002; 8 (7): 340-5.
9. Wagner EF, Karsenty G., Genetic control of skeletal development. Curr Opin Genet Dev. 2001; 11 (5): 527-32.
10. Franceschi RT, Xiao G., Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem. 2003; 88 (3): 446-54.
11. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G., Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997; 89 (5): 747-54.
12. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93 (2): 165-76.
13. Tanaka S, Takahashi N, Udagawa N, et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest. 1993; 91 (1): 257-63.
14. Biskobing DM, Fan X, Rubin J., Characterization of MCSF-induced proliferation and subsequent osteoclast formation in murine marrow culture. J Bone Miner Res. 1995; 10 (7): 1025-32.
15. Novack DV, Teitelbaum SL., The osteoclast: friend or foe ? Annu Rev Pathol. 2008; 3: 457-84.
16. Kim N, Kadono Y, Takami M, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med. 2005; 202 (5): 589-95.
17. Mizukami J, Takaesu G, Akatsuka H, et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol. 2002; 22 (4): 992-1000.
18. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K., The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature. 1999; 398 (6724): 252-6.
19. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3 (6): 889-901.
20. Srinivas G, Babykutty S, Sathiadevan PP, Srinivas P., Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007; 27 (5): 591-608.
21. Kuo YC, Meng HC, Tsai WJ., Regulation of cell proliferation, inflammatory cytokine production and calcium mobilization in primary human T lymphocytes by emodin from Polygonum hypoleucum Ohwi. Inflamm Res. 2001; 50 (2): 73-82.
22. Huang HC, Lee CR, Chao PD, Chen CC, Chu SH., Vasorelaxant effect of emodin, an anthraquinone from a Chinese herb. Eur J Pharmacol. 1991; 205 (3): 289-94.
23. Lee SU, Shin HK, Min YK, Kim SH., Emodin accelerates osteoblast differentiation through phosphatidylinositol 3-kinase activation and bone morphogenetic protein-2 gene expression. Int Immunopharmacol. 2008; 8 (5): 741-7.
24. Hwang JK, Noh EM, Moon SJ, et al. Emodin suppresses inflammatory responses and joint destruction in collagen-induced arthritic mice. Rheumatology (Oxford). 2013; 52 (9): 1583-91.
25. Vellaichamy E, Khurana ML, Fink J, Pandey KN., Involvement of the NF-kappa B/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A. J Biol Chem. 2005; 280 (19): 19230-42.
26. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R., Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25 (7): 1468-86.
27. Rodan GA, Martin TJ., Therapeutic approaches to bone diseases. Science. 2000; 289 (5484): 1508-14.
28. Rachner TD, Khosla S, Hofbauer LC., Osteoporosis: now and the future. Lancet. 2011; 377 (9773): 1276-87.
29. Boyle WJ, Simonet WS, Lacey DL., Osteoclast differentiation and activation. Nature. 2003; 423 (6937): 337-42.
30. Takayanagi H., Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007; 7 (4): 292-304.
31. Asagiri M, Sato K, Usami T, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med. 2005; 202 (9): 1261-9.
32. Arai A, Mizoguchi T, Harada S, et al. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment. J Cell Sci. 2012; 125 (Pt 12): 2910-7.
33. Lietman SA, Yin L, Levine MA., SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem Biophys Res Commun. 2008; 371 (4): 644-8.
34. Yamashita T, Yao Z, Li F, et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 2007; 282 (25): 18245-53.
35. Otero JE, Dai S, Alhawagri MA, Darwech I, Abu-Amer Y., IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J Bone Miner Res. 2010; 25 (6): 1282-94.
36. Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004; 10 (6): 617-24.
37. Hayden MS, Ghosh S., Signaling to NF-kappaB. Genes Dev. 2004; 18 (18): 2195-224.
38. Suda K, Woo JT, Takami M, Sexton PM, Nagai K., Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-alpha, IL-1, and RANKL. J Cell Physiol. 2002; 190 (1): 101-8.
39. Gersbach CA, Byers BA, Pavlath GK, García A., Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype. Exp Cell Res. 2004; 300 (2): 406-17.
40. Zheng H, Guo Z, Ma Q, Jia H, Dang G., Cbfa1/osf2 transduced bone marrow stromal cells facilitate bone formation in vitro and in vivo. Calcif Tissue Int. 2004; 74 (2): 194-203.
41. Ito Y, Zhang YW., A RUNX2/PEBP2alphaA/CBFA1 mutation in cleidocranial dysplasia revealing the link between the gene and Smad. J Bone Miner Metab. 2001; 19 (3): 188-94.
42. Lee HW, Suh JH, Kim HN, et al. Berberine promotes osteoblast differentiation by Runx2 activation with p38 MAPK. J Bone Miner Res. 2008; 23 (8): 1227-37.
43. Budagian V, Bulanova E, Brovko L, et al. Signaling through P2 × 7 receptor in human T cells involves p56lck, MAP kinases, and transcription factors AP-1 and NF-kappa B. J Biol Chem. 2003; 278 (3): 1549-60.
44. Bulanova E, Budagian V, Orinska Z, et al. Extracellular ATP induces cytokine expression and apoptosis through P2 × 7 receptor in murine mast cells. J Immunol. 2005; 174 (7): 3880-90.
45. Wilson HL, Francis SE, Dower SK, Crossman DC., Secretion of intracellular IL-1 receptor antagonist (type 1) is dependent on P2 × 7 receptor activation. J Immunol. 2004; 173 (2): 1202-8.
46. Grol MW, Panupinthu N, Korcok J, Sims SM, Dixon SJ., Expression, signaling, and function of P2 × 7 receptors in bone. Purinergic Signal. 2009; 5 (2): 205-21.
47. Reyes JP, Sims SM, Dixon SJ., P2 receptor expression, signaling and function in osteoclasts. Front Biosci (Schol Ed). 2011; 3: 1101-18.
48. Gartland A, Orriss IR, Rumney RM, Bond AP, Arnett T, Gallagher JA., Purinergic signalling in osteoblasts. Front Biosci (Landmark Ed). 2012; 17: 16-29.
49. Jørgensen NR, Henriksen Z, Sørensen OH, Eriksen EF, Civitelli R, Steinberg TH., Intercellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2 × 7 receptors. J Biol Chem. 2002; 277 (9): 7574-80.
50. Chiozzi P, Sanz JM, Ferrari D, et al. Spontaneous cell fusion in macrophage cultures expressing high levels of the P2Z/P2 × 7 receptor. J Cell Biol. 1997; 138 (3): 697-706.
51. Hoebertz A, Arnett TR, Burnstock G., Regulation of bone resorption and formation by purines and pyrimidines. Trends Pharmacol Sci. 2003; 24 (6): 290-7.
52. Gartland A, Buckley KA, Bowler WB, Gallagher JA., Blockade of the pore-forming P2 × 7 receptor inhibits formation of multinucleated human osteoclasts in vitro. Calcif Tissue Int. 2003; 73 (4): 361-9.
53. Panupinthu N, Rogers JT, Zhao L, et al. P2 × 7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. J Cell Biol. 2008; 181 (5): 859-71.
54. Ke HZ, Qi H, Weidema AF, et al. Deletion of the P2 × 7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol Endocrinol. 2003; 17 (7): 1356-67.